BA
The Boeing Company
BA's fundamentals are strong: its operating margin went from −10% to 10% and revenue grew 18%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
CSTE
Caesarstone Ltd.
There isn't enough reported data to score CSTE yet.
BA Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Stable | |
| Under pressure |
BA's profitability is currently healthy, and its revenue and cash flow are stable, but its balance sheet is under pressure.
CSTE Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Under pressure | |
| Weak |
CSTE's revenue, profitability, cash flow and balance sheet are all currently under pressure.
BA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 18x | $172 | — |
| Cheap | 51x | $496 | +189% |
| Fair | 82x | $790 | +360% |
| Expensive | 91x | $876 | +411% |
Historical ranges are pointers, not guarantees.
BA's PE is 18x, but its earnings don't support one, so it isn't a reliable read right now.
CSTE PE Valuation
CSTE has no meaningful PE right now: it lost money over the past year.
BA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Growth | |
| Improving | |
| Limited | |
| Low |
Analysts expect BA to return to profit, with revenue growing. However, they disagree widely on these estimates.
CSTE Forward outlook
There aren't enough analyst estimates for CSTE to show an outlook.
BA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $9.66 | +$23.38 |
| Q2 2026 | $2.78 | +$19.33 |
| Q1 2026 | $2.53 | +$20.49 |
| Q4 2025 | $2.48 | +$20.84 |
| Q3 2025 | -$13.72 | -$0.83 |
| Q2 2025 | -$16.55 | -$10.93 |
| Q1 2025 | -$17.96 | -$14.42 |
| Q4 2024 | -$18.36 | -$14.69 |
BA has the edge over CSTE on earnings quality, reporting a profit while its opponent remains loss making.
CSTE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$4.12 | -$2.49 |
| Q1 2026 | -$4.21 | -$2.85 |
| Q4 2025 | -$3.97 | -$2.83 |
| Q3 2025 | -$2.03 | -$0.03 |
| Q2 2025 | -$1.63 | +$0.28 |
| Q1 2025 | -$1.36 | +$1.80 |
| Q4 2024 | -$1.14 | +$1.98 |
| Q3 2024 | -$2.00 | +$1.80 |
CSTE lost $4.12 per share over the past year, a bigger loss than the year before.
BA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.2B | +3.9% |
| Q2 2026 | $24.6B | +8% |
| Q1 2026 | $22.2B | +14% |
| Q4 2025 | $23.9B | +57% |
| Q3 2025 | $23.3B | +30% |
| Q2 2025 | $22.7B | +35% |
| Q1 2025 | $19.5B | +18% |
| Q4 2024 | $15.2B | -31% |
BA has the edge over CSTE on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 1.5% | +22 points |
| Q2 2026 | 0.6% | +1.4 points |
| Q1 2026 | 2% | -0.3 points |
| Q4 2025 | 37% | +61 points |
| Q3 2025 | -21% | +12 points |
| Q2 2025 | -0.8% | +5.7 points |
| Q1 2025 | 2.4% | +2.9 points |
| Q4 2024 | -25% | -26 points |
BA has the edge over CSTE on profitability, with a higher operating margin.
CSTE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $96.6M | -4.5% |
| Q1 2026 | $88.7M | -11% |
| Q4 2025 | $94.4M | -3.5% |
| Q3 2025 | $102.1M | -5.1% |
| Q2 2025 | $101.1M | -15% |
| Q1 2025 | $99.6M | -16% |
| Q4 2024 | $97.9M | -24% |
| Q3 2024 | $107.6M | -24% |
CSTE's revenue has slid since its 2022 peak: $97M last quarter, down 4.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -5.6% | +4.9 points |
| Q1 2026 | -12% | +2.7 points |
| Q4 2025 | -18% | +5 points |
| Q3 2025 | -16% | -12 points |
| Q2 2025 | -11% | -2.8 points |
| Q1 2025 | -15% | -10 points |
| Q4 2024 | -23% | +2.4 points |
| Q3 2024 | -3.8% | -2.4 points |
CSTE's operating margin was −5.6% last quarter, up 4.9 points from the same quarter a year ago.
BA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $464M | +95% |
| Q2 2026 | $631M | +$831M |
| Q1 2026 | -$1.5B | +$836M |
| Q4 2025 | $375M | +$4.5B |
| Q3 2025 | $238M | +$2.2B |
| Q2 2025 | -$200M | +$4.1B |
| Q1 2025 | -$2.3B | +$1.6B |
| Q4 2024 | -$4.1B | -239% |
BA has the edge over CSTE on cash generation, producing positive trailing cash flow while its opponent burns cash.
CSTE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $1.6M | +$15.1M |
| Q1 2026 | -$7.3M | +$9.4M |
| Q4 2025 | -$10.1M | -$4.9M |
| Q3 2025 | -$5.8M | -147% |
| Q2 2025 | -$13.5M | -261% |
| Q1 2025 | -$16.8M | -382% |
| Q4 2024 | -$5.2M | -148% |
| Q3 2024 | $12.4M | -48% |
CSTE has burned cash in six of the last eight quarters: −$22M over the past year, against −$23M the year before.
BA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +2.1M shares |
| 1 year | +4.3% | +32.8M shares |
| 3 years | +31% | +186M shares |
| 5 years | +35% | +204M shares |
| Available history | +40% | +227M shares |
BA has 793M diluted shares, up 4.3% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
CSTE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +7.7K shares |
| 1 year | +0.1% | +24.9K shares |
| 3 years | +0.2% | +70.4K shares |
| 5 years | +0.1% | +44.9K shares |
| Available history | +0.4% | +142K shares |
CSTE has the edge over BA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
CSTE hasn't bought back shares in the past year.
BA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.0x | Elevated |
| Q2 2026 | 5.7x | High |
| Q1 2026 | 6.0x | High |
| Q4 2025 | 6.9x | High |
| Q2 2024 | 361.8x | High |
| Q1 2024 | 36.1x | High |
| Q4 2023 | 36.4x | High |
| Q3 2023 | 96.1x | High |
BA's net debt is about 3.0 years of its operating earnings (EBITDA), down from more than 20 years a year ago.
CSTE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2023 | 24.9x | High |
| Q1 2023 | 2.6x | Moderate |
| Q4 2022 | 2.5x | Moderate |
| Q3 2022 | 1.9x | Healthy |
| Q2 2022 | 1.7x | Healthy |
| Q1 2022 | 1.8x | Healthy |
| Q4 2021 | 1.8x | Healthy |
| Q3 2021 | 1.0x | Healthy |
CSTE's net debt is more than 20 years of its operating earnings (EBITDA), up from 1.7 years a year ago.
BA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 31.1 | Neutral |
| Stochastic | 9.6 | Oversold |
BA's weekly RSI is 31 (neutral) and its Stochastic is 10 (oversold).
CSTE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 35.2 | Neutral |
| Stochastic | 4.9 | Oversold |
CSTE's weekly RSI is 35 (neutral) and its Stochastic is 5 (oversold).
BA PE vs Industrials Sector
| Metric | BA | Sector median | Relative |
|---|---|---|---|
| PE | 18x | 24x | 26% below |
| PE % | 0 | 58 | 58 pts below |
BA is trading at 18x earnings, a 26% discount to the Industrials sector's median of 24x, though its earnings don't support one.
CSTE PE vs Industrials Sector
| Metric | CSTE | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 24x | — |
CSTE has no meaningful PE right now: it lost money over the past year.
BA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $184.6 | 7.1% below |
| 20 week MA | $203.8 | 16% below |
| 50 week MA | $215.5 | 20% below |
| 100 week MA | $205.9 | 17% below |
| 200 week MA | $200.6 | 14% below |
BA is in a downtrend: it's below all five of its weekly moving averages, and 14% below its 200-week average.
CSTE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.21 | 41% below |
| 20 week MA | $2.51 | 48% below |
| 50 week MA | $2.00 | 35% below |
| 100 week MA | $2.19 | 41% below |
| 200 week MA | $3.47 | 63% below |
CSTE is in a downtrend: it's below all five of its weekly moving averages, and 63% below its 200-week average.
BA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $330.1 | $217.2 | -34% |
| 2021 | $217.2 | $204.2 | -6% |
| 2022 | $204.2 | $189.1 | -7.4% |
| 2023 | $189.1 | $260.7 | +38% |
| 2024 | $260.7 | $180.7 | -31% |
| 2025 | $180.7 | $216.4 | +20% |
| 2026 YTD | $216.4 | $171.6 | -21% |
BA has the edge over CSTE on returns for 2026, with the stronger performance.
CSTE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $14.9 | $11.0 | -26% |
| 2021 | $11.0 | $11.2 | +2.4% |
| 2022 | $11.2 | $5.83 | -48% |
| 2023 | $5.83 | $3.74 | -36% |
| 2024 | $3.74 | $4.42 | +18% |
| 2025 | $4.42 | $1.71 | -61% |
| 2026 YTD | $1.71 | $1.30 | -24% |
CSTE has finished lower in four of the last six years. It's down 24% so far in 2026.